Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 74.71 (+3.71), LXRX: 1.35 (+0.03), AMGN: 144.09 (+6.58), REGN: 381.01 (+14.88), EXEL: 1.60 (-0.05)
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
Business Wire - Tue Oct 14, 3:12PM CDT
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 1.60 (-0.05)
Is Exelixis, Inc. Stock a Bad News Buy?
Motley Fool Staff - Motley Fool - Mon Oct 13, 7:30AM CDT
Clinical or regulatory setbacks can cause biotechnology stocks to crash in a hurry. On occasion, the market's pessimism isn't entirely warranted, setting the stock up for an equally impressive comeback. Deciphering which "bad news biotechs" are...
BMY: 51.95 (+1.39), EXEL: 1.60 (-0.05)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.51 (+0.45), VVUS: 3.47 (+0.02), NPSP: 28.69 (+0.24), ARNA: 4.16 (-0.01), EXEL: 1.60 (-0.05)
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:50AM CDT
Roche recently announced encouraging preliminary combination data from a phase Ib study on cancer immunotherapy candidate MPDL3280A (anti-PDL1) in combination with Avastin.
JNJ: 100.36 (+1.16), BMY: 51.95 (+1.39), EXEL: 1.60 (-0.05)
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:41AM CDT
Exelixis (EXEL) Is in Oversold Territory: What’s Next?
EXEL: 1.60 (-0.05)
Thyroid Cancer Market Analysis - API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sgp9d/thyroid_cancer) has announced the addition of the "Thyroid Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Thyroid Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Exelixis, Inc. - Pfizer Inc. - Genzyme Corporation - Bracco Diagnostics Inc. - Mallinckrodt plc - Sandoz Inc. - Forest Laboratories, Inc. - Institut Biochimique SA - Jubilant DraxImage Inc. For more information visit http://www.researchandmarkets.com/research/5s...oid_cancer
PFE: 28.28 (+0.35), FRX: 99.00 (-0.77), EXEL: 1.60 (-0.05)
Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
CLVS: 51.09 (+1.75), MRK: 55.13 (+1.08), AZN: 69.00 (+1.05), BMY: 51.95 (+1.39), EXEL: 1.60 (-0.05)
Market Maker Surveillance Report. EXEL, INTC, KMI, MSFT, ACI, XRX, Bullishly Biased Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:58AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Exelixis Inc (NASDAQ:EXEL), INTEL CORPORATION (NASDAQ:INTC), KINDER MORGAN INCORPORATED (NYSE:KMI), MICROSOFT CORPORATION (NASDAQ:MSFT), Arch Coal Inc (NYSE:ACI), Xerox Corp (NYSE:XRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KMI: 38.31 (+0.74), ACI: 1.93 (+0.01), XRX: 13.20 (+0.52), MSFT: 44.88 (+0.80), INTC: 32.61 (+1.03), EXEL: 1.60 (-0.05)
Exelixis Up 7.7%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Mon Sep 29, 10:09AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 7.7% to $1.68 on 1.1x average daily volume. Thus far today, Exelixis has traded 5.7 million shares, vs. average volume of 5.2 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's -0.5%) and outperformed the S&P 500 (7.7% to the S&P's -0.4%) during today's trading.
EXEL: 1.60 (-0.05)
Why Exelixis, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Mon Sep 29, 9:38AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of small-cap biopharma Exelixis spiked by...
EXEL: 1.60 (-0.05)
Ahead of the Bell: Exelixis shares soar
AP - Mon Sep 29, 8:19AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) — Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
EXEL: 1.60 (-0.05)
Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Mon Sep 29, 2:00AM CDT
--- CoBRIM results will be presented today during the Presidential Symposium at the European Society for Medical Oncology (ESMO) and published in the New England Journal of Medicine -
EXEL: 1.60 (-0.05)
Anaplastic Thyroid Cancer Therapeutics Pipeline Review 2014 - 7 Companies & 11 Drug profiles
M2 - Wed Sep 24, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkn9d/anaplastic) has announced the addition of the "Anaplastic Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Plexxikon Inc. - Exelixis, Inc. - OXiGENE, Inc. - Genelux Corporation - Immune Pharmaceuticals, Inc. Drug Profiles - fosbretabulin tromethamine - efatutazone - cabozantinib s-malate - crolibulin - (dabrafenib mesylate trametinib dimethyl sulfoxide) - PLX-8394 - GLONC-2 - PLX-4720 - CLM-3 - CLM-94 - AY-4 For more information visit http://www.researchandmarkets.com/research/9mkn9d/anaplastic
OXGN: 2.03 (+0.11), IMNP: 2.95 (-0.07), GSK: 43.63 (+0.02), EXEL: 1.60 (-0.05)
Why Exelixis (EXEL) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:53AM CDT
Exelixis is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
EXEL: 1.60 (-0.05)
Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress
Business Wire - Wed Sep 17, 12:00AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced that cobimetinib, an Exelixis-discovered compound, will be the subject of a clinical data presentation at the European Society for Medical Oncology (ESMO) 2014 Congress. During the meeting, which will be held from September 26-30, 2014, in Madrid, Spain, investigators will present initial data from coBRIM, the ongoing phase 3 pivotal trial of cobimetinib in combination with vemurafenib in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
EXEL: 1.60 (-0.05)
Hot Stock: Exelixis, Shares Drop 6.6% (EXEL)
Comtex SmarTrend(R) - Tue Sep 16, 12:42PM CDT
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 6.6% to $1.63 on 1.0x average daily volume. Thus far today, Exelixis has traded 4.7 million shares, vs. average volume of 4.5 million shares per day. The stock has underperformed the Dow (-6.6% to the Dow's 0.8%) and underperformed the S&P 500 (-6.6% to the S&P's 0.9%) during today's trading.
EXEL: 1.60 (-0.05)
Why Exelixis Inc. Stock Crashed By 70% in 2014
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 13, 9:00AM CDT
The benchmark S&P 500 may have crossed the psychological 2,000 point mark, and the Dow Jones Industrial Average have crested 17,000, but it's been an abysmal year if you're a shareholder in Exelixis , like I am. EXEL data by ...
EXEL: 1.60 (-0.05)
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
NVAX: 4.99 (-0.02), DNDN: 1.10 (-0.03), ARNA: 4.16 (-0.01), FOLD: 5.82 (-0.12), EXEL: 1.60 (-0.05)
Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9
Business Wire - Mon Sep 08, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Morgan Stanley Global Healthcare Conference taking place September 8-10 in New York. The Exelixis presentation is scheduled for 11:45 a.m. EDT/8:45 a.m. PDT tomorrow, Tuesday, September 9, 2014.
EXEL: 1.60 (-0.05), MS: 34.06 (+0.74)